SCHEMBL6992569

SCHEMBL6992569

CC1Oc2ccc(-c3cccnc3)cc2NC1=O

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 4/20 0.54
PDE3A Q14432 4/20 0.54
PARP1 P09874 2/20 0.51
CYP11B1 P15538 10/20 0.49
CYP11B2 P19099 10/20 0.49
CYP1A2 P05177 3/20 0.46
CYP2C9 P11712 1/20 0.45
TBXAS1 P24557 1/20 0.45
MAPT P10636 1/20 0.44
TSHR P16473 1/20 0.44
HSD17B10 Q99714 1/20 0.44
AURKA O14965 1/20 0.43
TTK P33981 1/20 0.43
AURKB Q96GD4 1/20 0.43
INCENP Q9NQS7 1/20 0.43
KDR P35968 1/20 0.43
BACE1 P56817 1/20 0.42
CYP19A1 P11511 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7711311 0.85 CYP11B1 (0.48) PDE3BPDE3ACYP11B1CYP11B2CYP1A2
SCHEMBL7001705 0.84 PARP1 (0.64) PDE3BPDE3APARP1KDR
SCHEMBL20137948 0.79 CYP11B2 (0.41) PDE3BPDE3APARP1CYP11B1CYP11B2
SCHEMBL6992017 0.76 PARP1 (0.75) PDE3BPDE3APARP1CYP1A2MAPT
SCHEMBL21722859 0.76 PARP1 (0.60) PDE3BPDE3APARP1MAPTTSHR
SCHEMBL532007 0.76 KDR (0.53) PDE3BPDE3APARP1MAPTKDR
SCHEMBL6992024 0.76 PARP1 (0.44) PDE3BPDE3APARP1MAPTTSHR
SCHEMBL532908 0.76 PARP1 (0.55) PDE3BPDE3APARP1MAPTTSHR
SCHEMBL532744 0.75 KDR (0.52) PDE3BPDE3APARP1KDR
SCHEMBL6992019 0.75 PARP1 (0.51) PDE3BPDE3APARP1MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1015437-B1 BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS SCHERING AG (DE) 2003-12-03 EP disclosed
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed